Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

two hands trying to connect couple puzzle piece with sunset background. Jigsaw alone wooden puzzle against sun rays. one part of whole. symbol of association and connection. business strategy.
Gilead's Immunomedics buy gives it a key piece in its oncology strategy – a late-stage solid tumor asset

Gilead Sciences, Inc. entered into partnership negotiations with Immunomedics, Inc. six months ago and emerged from those discussions on 13 September with plans to buy the company for $21bn, giving the biotechnology giant its first approved solid tumor therapy – the Trop2-targeting antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan) for third-line metastatic triple-negative breast cancer (TNBC).

Gilead CEO Daniel O’Day said during a same-day conference call with analysts and investors to discuss the deal that the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Partnered By

Nancy Testing Partnered Content

This is a short description.

Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

 
• By Kevin Grogan

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.